Zhenghong Technology Completes New Round of Financing and Advances Confidently in the Ophthalmology Sector

VCBeat learned at the first time,BeijingZhenghongTechnologyCo., Ltd. recently completed a new round of financing，The lead investor isInnovation Companion Fund, with the follow-up investment from existing shareholders.GreenShanghai Greenriver Investment Co., Ltd.、Shanghai Xingang Investment,TakeVCBeat Served as Financial Advisor。ThisWheelInvestment willBoosting ZhenghongTechnology inNewProduct Development, Mass Production, Marketingand other aspectsTheAccelerationAdvance,In boomingStay on the developing ophthalmology trackLeadingCompetitive position.

Beijing Zhenghong Technology Co., Ltd. oversees two major sectors, one of which is Guangdong Weiren Medical Technology Co., Ltd.Ophthalmic Optical Imaging Platform，Gathered atInOphthalmologyOCTCore OpticalImaging EquipmentResearch and Production; Tianjin Ushi Ophthalmic Technology Co., Ltd. isOphthalmic Innovation Materials Platform,FormationFinishedChinaChina's first innovative QingLightOphthalmic MicrocatheterProductLineBeijing Zhenghong Technology Co., Ltd. has a top-tier technical team of returned overseas Ph.D.s, mastering the world's most advanced core optical imaging technology. It develops high-end medical imaging equipment with international competitiveness and has established a technical platform for eye disease examination, intelligent diagnosis, and eye disease treatment. This forms a product layout with broad development prospects. In the future, the company will continuously improve integrated eye disease screening and treatment solutions, covering the entire value chain of ophthalmic diagnosis and treatment.

Dr. An Lin, Co-founder of Beijing Zhenghong Technology Co., Ltd., graduated from the Department of Bioengineering at the University of Washington, USA, under the tutelage of internationally renowned expert and senior member of the Optical Society of America, Professor Ricky Wang. Over the years, Dr. An has been dedicated to technical research in the field of OCT and is a senior expert in Optical Coherence Tomography (OCT). Building on OCT technology, Dr. An made several breakthroughs in OCT Angiography (OCTA), enabling OCT to achieve functional imaging of retinal capillaries alongside structural imaging. This advancement represents one of the most significant breakthroughs in the ophthalmic OCT field over the past decade. Dr. An has published 39 papers in high-level international optical journals such as Optics Letters, with abundant research achievements. After returning to China to start his business, Dr. An was selected for the National Young Special Expert Program, awarded the Guangdong Province May Fourth Youth Medal, and included in the "Guangdong Province Pearl River Talent Team Program." His entrepreneurial project received strong support from the Guangdong provincial government, securing subsidies totaling more than 50 million yuan.

Dr. An Lin once worked for the renowned optical manufacturer Zeiss and, as a key researcher, developed the world's first-generation OCTA product. He successfully completed the product’s development, registration, and market launch. This product is currently the ophthalmic OCTA device with the largest global installed base and has gained widespread recognition and high praise from customers. Since its establishment, Guangdong Weiren, led by Dr. An Lin, has brought together a group of returned overseas Ph.D.s, forming a strong technical team. The team has exceptional expertise in optical design, system design, algorithm research, and AI technology. Their R&D experience spans hardware, software, and systems, showcasing world-class R&D capabilities.

Mr. Guang Li, Co-founder of Beijing Zhenghong Technology Co., Ltd., has twenty years of experience in the medical device industry. He previously served as the Vice President of Natong Medical Group, a well-known medical device company in China. His expertise spans product marketing, product line management, research and development, and production, with comprehensive experience in managing the entire product value chain. He has been a profound witness, active participant, and key contributor to the rapid growth of China's medical device industry. Mr. Guang Li holds a full-time MBA degree from Jilin University and has deep expertise in business planning and corporate governance, with extensive experience in company operations and management. In response to the rapid development phase of the ophthalmic medical market, Mr. Guang Li entered the ophthalmology field to co-found a business, demonstrating the ability to build a platform-type company specializing in ophthalmic equipment and treatment consumables.

The entrepreneurial team of Zhenghong Technology combines industry technical experts with seasoned marketing professionals, possessing both strong technical R&D capabilities and solid industrialization experience, which provides a unique advantage and drive for the rapid development of the company.

Beijing Zhenghong Technology Co., Ltd. has formed a dual-line product layout of equipment and consumables, and is committed to building a hardware and software product system covering the entire process of ophthalmic diagnosis and treatment.

Ophthalmic OCT has been gradually widely popularized in clinical applications, becoming an important technical means for the diagnosis of fundus diseases. The OCTA series developed by Guangdong Weiren is the globally optimal performance spectral-domain OCTA and the most competitive product to achieve import substitution.Frequency DomainTechnology with itsA relatively mature technical level and more complex system capabilities are crucial for global ophthalmic OCT commercialization.ChemicalThe MasterFlow RouteRelying on its excellent technical expertise and comprehensive product development experience, Guangdong Weiren, supported by top international technical experts in the OCT field and domestic ophthalmology clinical experts, has achieved world-class core technical indicators for its products. Its products demonstrate superior performance and comprehensive functionality. Guangdong Weiren's OCT and OCTA products have both obtained product registration certificates, meeting the clinical needs of medical institutions at various levels in China.Only BenevolenceTheHighCost-effectivenessProduct, which is highly consistent with OCTEquipmentRapidly Sinking to the GrassrootsHospitalThe Trend, which is highly competitive for both imported products and other domestically produced brands.

Guangdong Weiren has simultaneously completed the development of swept-source OCT, and the product is currently undergoing the registration process. It is the only company in China that possesses both spectral-domain technology and swept-source technology. The two types of OCT will cover a broader market and provide customers with multiple choices. The anterior segment OCT product developed by Guangdong Weiren can meet the measurement of various parameters of the anterior segment, offering advantages such as high measurement accuracy, multifunctional integration, and low cost. The widespread application of the anterior segment OCT product will change the current situation where there are many anterior segment examination devices with single functions.

Guangdong Weiren is committed to the development of ophthalmic AI technology. By empowering devices with intelligent eye-tracking and smart clear imaging, it makes OCT equipment imaging clearer and faster, improves diagnostic accuracy, enhances the core competitiveness of products, and increases product usability. By empowering doctors through intelligent retinal layering, abnormality screening and diagnosis, and automatic disease diagnosis, it reduces repetitive labor for doctors, improves diagnostic efficiency, minimizes misdiagnosis and missed diagnosis, and increases the detection rate of abnormalities. Through the gradual application of AI technology and the development of higher-level algorithms, the overall diagnostic and treatment efficiency and standards in ophthalmology are improved.

China currently has over 20 million glaucoma patients. As an irreversible blinding eye disease, glaucoma poses significant risks, and its incidence is on the rise. The glaucoma treatment market is an area with unmet needs, lacking targeted drugs and advanced treatment technologies, with various methods having certain limitations. Trabeculectomy is a commonly used surgical method but has limited efficacy in lowering intraocular pressure and notable side effects. In recent years, a new type of minimally invasive glaucoma surgery that does not rely on filtering blebs—canaloplasty—has emerged as a novel concept in clinical treatment. This procedure involves using a specialized microcatheter to dilate and open Schlemm's canal and the trabecular meshwork, restoring the natural outflow pathway of aqueous humor, thereby reducing intraocular pressure. Over a decade of clinical application has confirmed that canaloplasty offers effective and safe intraocular pressure reduction.

The microcatheter system, pioneered by Tianjin Ushi, was jointly developed with experts from Beijing Tongren Hospital. It addresses a series of complex integrated catheter technical challenges, featuring intricate processing techniques and high-precision process control. The tip of the microcatheter emits light that can penetrate the sclera, enabling guidance for surgeries outside the sclera; the injection system precisely administers viscoelastic agents; the catheter is capable of 360-degree bending with a length of up to 760 millimeters, meeting surgical needs for congenital glaucoma and other indications. The microcatheter product facilitates various methods of trabeculotomy procedures, providing robust support for the advancement of trabeculoplasty.

TianjinThe OptiVision Glaucoma Microcatheter has completed clinical trials.Test，Clinical Trial StatisticsThe results are good, and it is currently in the registration and application phase.，Is expected to become a leading player in ChinaFirstPaymentBlueIntraocular DrainageMicroCreate products.The product's safe, effective, and minimally invasive technical advantages will bring a revolutionary push to glaucoma treatment, with enormous future development potential.

In 2020, the overall scale of China's ophthalmology medical market approached 200 billion yuan, experiencing a high-growth phase with rapid expansion. Among this, the market size for ophthalmic devices reached 30 billion yuan, with an annual growth rate exceeding 20%. The ophthalmology sector is becoming a golden segment within the medical market. With the rise of domestic ophthalmic technology and brands, driven by the increasing demand for ophthalmic diagnosis and treatment, and guided by government policies encouraging the procurement of domestically produced medical devices at multiple levels, domestic ophthalmic companies are also set to experience significant development. Companies with strong technological innovation capabilities and excellent commercial operational abilities will stand out.

Beijing Zhenghong Technology Co., Ltd. gradually constructs a product planning layout for integrated diagnosis and treatment, covering the entire process of ophthalmic diagnosis and treatment and the full chain of eye health management. It forms an all-round layout of inspection equipment, treatment equipment, and treatment consumables in optometry examination, eye disease screening, diagnosis, treatment/surgery, and follow-up monitoring of eye diseases. The company specifically develops high-tech barrier and high value-added products to promote the domestic production of ophthalmic devices and technological self-sufficiency in China. Relying on ophthalmic AI technology, Beijing Zhenghong Technology Co., Ltd. develops more functions, connects more scenarios, and advances the standardization, informatization, and intelligence of the whole process of eye health management.

With each passing day bringing new developments, and numerous competitors vying for the lead, we look forward to Beijing Zhenghong Technology Co., Ltd. making great strides and taking a leading position in the ophthalmology sector!

Chengwei Venture Fund Focuses on Early and Mid-Stage Investments in the Healthcare Industry. The fund is committed to investing in innovative companies driven by core products, technology, and market forces, while respecting the fundamental logic of projects. The fund’s partners include Chengwei Capital, Shanghai Municipal Guidance Fund, Putuo District Guidance Fund, and Zhangjiang Hi-Tech.

Shanghai Greenriver Investment Co., Ltd. is a private equity investment firm that focuses on early-stage and hard technology investments. Established in 2007, the company has invested billions of yuan across various sectors including biomedicine, new energy, new materials, semiconductors, and high-end manufacturing, supporting over 70 science and technology innovation enterprises. Shanghai Greenriver Investment actively aligns with national strategies to promote the development of China’s technology-driven industries, making forward-looking investments in emerging sectors and facilitating effective collaboration between tech talent and capital. Believing in "technology creates value, growth enhances value," the firm adopts an active yet passive investment approach, committing to long-term partnerships for shared growth.

QuShi Capital,隶属于 QuShi Holdings Group, is the group's boutique investment banking services division. It has successively served dozens of top-tier companies, including HaiJieYa, New羿 BioTech, SuoSi Medical, JinShi Technology, DeLaiSen, YunYi Medical, HuXiu Technology, LeYan Technology, HeMa Programming, and 36Kr Whale Accuracy, securing billions in financing from renowned domestic and international funds. Investors include: China Guoxin, Hillhouse Capital, Sequoia China, Yunfeng Fund, HuaChuang Capital, Orchid Asia, CMB International, CNPharm Capital, Boyuan Capital, Lilly Asia, Yuanhe Holdings, etc.

QuShi Holdings Group is committed to becoming a top-tier research-oriented holding group. The company's businesses include boutique investment banking services · QuShi Capital, primary market equity investment · QuShi Growth Fund, secondary market equity investment · RedState Capital, research services · QuShi Research Institute, and physical and incubation industries · QuShi Industry. The company positions itself as a comprehensive service platform behind China's top entrepreneurs.